Get the Stockscreener App
1.60
1.84%
-0.03
Akoya Biosciences Inc stock is traded at $1.60, with a volume of 246.23K.
It is down -1.84% in the last 24 hours and down -41.61% over the past month.
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
See More
Previous Close:
$1.63
Open:
$1.6
24h Volume:
246.23K
Relative Volume:
0.38
Market Cap:
$76.85M
Revenue:
$96.63M
Net Income/Loss:
$-63.32M
P/E Ratio:
-1.0959
EPS:
-1.46
Net Cash Flow:
$-54.55M
1W Performance:
-12.09%
1M Performance:
-41.61%
6M Performance:
-32.77%
1Y Performance:
-73.47%
1-Day Range:
$1.55
$1.65
1-Week Range:
$1.55
$1.83
52-Week Range:
$1.55
$6.31
Akoya Biosciences Inc Stock (AKYA) Company Profile
Name
Akoya Biosciences Inc
Sector
Industry
Phone
855.896.8401
Address
100 CAMPUS DRIVE, MARLBOROUGH
Compare AKYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKYA
Akoya Biosciences Inc
|
1.60 | 76.85M | 96.63M | -63.32M | -54.55M | -1.46 |
|
ISRG
Intuitive Surgical Inc
|
579.18 | 205.74B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
229.53 | 65.11B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
94.78 | 46.26B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
234.82 | 34.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
92.42 | 18.19B | 3.90B | 392.30M | 288.10M | 1.95 |
Akoya Biosciences Inc Stock (AKYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-06-24 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-06-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-21-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Feb-02-23 | Initiated | UBS | Buy |
| Nov-03-22 | Initiated | CapitalOne | Overweight |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Jun-22-22 | Initiated | BTIG Research | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| May-11-21 | Initiated | Canaccord Genuity | Buy |
| May-11-21 | Initiated | JP Morgan | Overweight |
| May-11-21 | Initiated | Morgan Stanley | Overweight |
| May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Akoya Biosciences Inc Stock (AKYA) Latest News
Quanterix Highlights Benefits Of Akoya Biosciences Acquisition -March 03, 2025 at 06:13 am EST - Marketscreener.com
Can Quanterix's Akoya Acquisition Transform Biomarker Detection and Deliver $1B Revenue? - StockTitan
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 60.1% in February - Defense World
Akoya Biosciences (AKYA) to Release Earnings on Monday - MarketBeat
Akoya Biosciences' Merger with Quanterix Moves Forward By Investing.com - Investing.com South Africa
Quanterix advances towards Akoya Biosciences acquisition By Investing.com - Investing.com South Africa
Akoya Biosciences’ Merger with Quanterix Moves Forward - Investing.com India
Akoya Biosciences' Merger with Quanterix Moves Forward - Investing.com
Quanterix advances towards Akoya Biosciences acquisition - Investing.com
Akoya Biosciences’ Merger with Quanterix Moves Forward By Investing.com - Investing.com UK
Akoya Biosciences stock hits 52-week low at $1.88 amid market challenges - Investing.com Australia
AKYA Stock Update: Akoya Biosciences Inc’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Akoya climbs after merger deal with Quanterix - MSN
Quanterix Merger Battle: 5.9% Stakeholder Reveals Why $42M Deal Could Destroy Shareholder Value - StockTitan
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Update - Defense World
12,325 Shares in Akoya Biosciences, Inc. (NASDAQ:AKYA) Bought by SG Americas Securities LLC - Defense World
Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook - br.ADVFN.com
AKYAAkoya Biosciences Reports Second Quarter 2024 Financial Results - br.ADVFN.com
Akoya Biosciences Inc (AKYA)’s Day in Review: Closing at 2.34, Down by -4.88 - The Dwinnex
Akoya Biosciences Inc (AKYA) Shares Plummet Below 1-Year High - The News Heater
Akoya Biosciences unveils strategic product roadmap - Yahoo Finance
Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels - GlobeNewswire
Akoya Biosciences Expands Product Offering with New High-Plex Neurobiology Panels for Human and Mouse Applications - Nasdaq
Revolutionary Neurobiology Panels: Akoya's New Weapon Against Brain Disease Research - StockTitan
Akoya Biosciences, Inc. (NASDAQ:AKYA) Sees Significant Increase in Short Interest - MarketBeat
Akoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing Partner - Business Wire
Major Breakthrough: Akoya's Advanced Diagnostic Tech Gets Manufacturing Powerhouse Backing - StockTitan
Quanterix Nears All-Stock Deal for Akoya Biosciences - MSN
Spatial Proteomics Market Report and Competitive Landscape 2025-2030, with 10X Genomics, Bruker, Fluidigm, Akoya Biosciences, PerkinElmer, Biotechne, S2 Genomics, Seven Bridges Genomics & More - Yahoo Finance
Barclays PLC Buys 30,095 Shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) - Defense World
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Rating of “Hold” from Analysts - Defense World
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Jane Street Group LLC Decreases Stock Holdings in Akoya Biosciences, Inc. (NASDAQ:AKYA) - Defense World
Akoya Biosciences (NASDAQ:AKYA) Cut to Hold at Canaccord Genuity Group - Defense World
Akoya Biosciences (NASDAQ:AKYA) Downgraded by Canaccord Genuity Group to Hold - MarketBeat
Major Player in the Spatial Biology Market Analysis by Type, - openPR
Akoya Biosciences to be acquired by Billerica research firm, create $220M business - Worcester Business Journal
Quanterix merging with Akoya to bolster biomarker portfolio - BioWorld Online
Quanterix announces acquisition of Akoya Biosciences By Investing.com - Investing.com Canada
Quanterix announces acquisition of Akoya Biosciences - Investing.com
Billerica diagnostics maker Quanterix to acquire Marlborough biotech - The Business Journals
Akoya Biosciences (NASDAQ: AKYA) Enters Merger Agreement with Quanterix Corporation - Defense World
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates SSTK, ACCD, ESSA, AKYA on Behalf of Shareholders - GlobeNewswire Inc.
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates ESSA, AKYA, CCNE, QTRX on Behalf of Shareholders - The Malaysian Reserve
$TOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the MergerACCD, QTRX, AKYA, ESSA - Markets Insider
Quanterix Agrees to Buy Life Sciences Firm Akoya Biosciences - MSN
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc.AKYA - Business Wire
Quanterix Is Close to All-Stock Deal for Akoya Bioscience - MSN
Akoya Biosciences Inc Stock (AKYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Akoya Biosciences Inc Stock (AKYA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McKelligon Brian | President and CEO |
Jun 11 '24 |
Sale |
2.08 |
7,500 |
15,630 |
224,733 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
232,233 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Sale |
2.01 |
7,500 |
15,064 |
224,733 |
| McKelligon Brian | President and CEO |
Mar 20 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
239,368 |
| McKelligon Brian | President and CEO |
Mar 20 '24 |
Sale |
4.97 |
7,500 |
37,243 |
231,868 |
| McKelligon Brian | President and CEO |
Mar 13 '24 |
Sale |
4.94 |
7,500 |
37,035 |
224,368 |
3.44%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):